Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ancient chinese medicine predict lung cancer drug success?

NCT ID NCT07338396

Knowledge-focused Sponsor: Guangzhou University of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how Traditional Chinese Medicine (TCM) body patterns, like tongue and pulse readings, relate to how well targeted lung cancer drugs work. About 3000 people with a specific type of lung cancer will be followed for up to 5 years. Researchers will collect TCM information and samples to find links between these patterns and treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll approximately 3000 adult patients with EGFR-mutant non-small cell lung cancer (NSCLC) who are initiating standard EGFR-TKI therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pathologically or histologically confirmed non-small cell lung cancer (NSCLC) * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Presence of epidermal growth factor receptor (EGFR) mutation confirmed by genetic testing Postoperative Cohort (must meet all of the above and the following): * Have undergone curative surgery for lung cancer with R0 resection * Are planned to receive or are currently receiving postoperative EGFR-TKI adjuvant therapy within 2 weeks Advanced Cohort (must meet all of the above and the following): * Meet stage IIIB-IV criteria according to the 9th edition of the American Joint Committee on Cancer (AJCC), or have stage IIIB or below disease but have refused or are unable to tolerate surgical treatment * Have at least one measurable lesion * Are planned to receive or are currently receiving first-line EGFR-TKI therapy within 2 weeks Exclusion Criteria: * Unable to comply with baseline assessments * Pregnant or breastfeeding women * Presence of other uncontrolled malignancies * Presence of severe brain diseases or psychiatric disorders that affect the patient's ability to communicate or provide informed consent * Individuals without legal capacity, or those with medical or ethical reasons preventing continued participation in the study * Refusal to sign the informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Xinxiang Medical University, Henan province

    Weihui, Henan, China

  • Beijing chest Hospital

    Beijing, Beijing Municipality, 100000, China

  • Guang'anmen Hospital of china Academy of chinese Medical Sciences

    Beijing, Beijing Municipality, 100000, China

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    Guangzhou, Guangdong, 510000, China

  • Sichuan Cancer Hospital and Research Institute

    Chengdu, Sichuan, 610040, China

  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

    Shanghai, Shanghai Municipality, 200437, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.